CCCC C4 Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CCCC

Price (delayed)

$6.74

Market cap

$462.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$403.31M

C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment ...

Highlights
The company's debt fell by 19% YoY
The EPS has increased by 2.9% since the previous quarter
CCCC's gross profit is down by 33% year-on-year but it is up by 2% since the previous quarter
The company's revenue fell by 33% YoY but it rose by 2% QoQ
The quick ratio has declined by 14% since the previous quarter
CCCC's net income is down by 3.4% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.c4thera.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CCCC
Market
Shares outstanding
68.6M
Market cap
$462.37M
Enterprise value
$403.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
16.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.43
Earnings
Revenue
$20.76M
EBIT
-$129.84M
EBITDA
-$121.8M
Free cash flow
-$108.55M
Per share
EPS
-$2.67
Free cash flow per share
-$2.19
Book value per share
$4.99
Revenue per share
$0.42
TBVPS
$7.58
Balance sheet
Total assets
$376.45M
Total liabilities
$130.34M
Debt
$70.98M
Equity
$246.11M
Working capital
$228.42M
Liquidity
Debt to equity
0.29
Current ratio
6.34
Quick ratio
6.29
Net debt/EBITDA
0.48
Margins
EBITDA margin
-586.8%
Gross margin
100%
Net margin
-638.3%
Operating margin
-669.8%
Efficiency
Return on assets
-35.8%
Return on equity
-55.3%
Return on invested capital
-38.9%
Return on capital employed
-38.9%
Return on sales
-625.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CCCC stock price

How has the C4 Therapeutics stock price performed over time
Intraday
4.82%
1 week
9.24%
1 month
-14.68%
1 year
114.65%
YTD
19.29%
QTD
-17.5%

Financial performance

How have C4 Therapeutics's revenue and profit performed over time
Revenue
$20.76M
Gross profit
$20.76M
Operating income
-$139.03M
Net income
-$132.49M
Gross margin
100%
Net margin
-638.3%
The operating margin has plunged by 61% YoY but it has grown by 2.6% from the previous quarter
The company's net margin has shrunk by 55% YoY but it rose by 3.7% QoQ
CCCC's gross profit is down by 33% year-on-year but it is up by 2% since the previous quarter
The company's revenue fell by 33% YoY but it rose by 2% QoQ

Growth

What is C4 Therapeutics's growth rate over time

Valuation

What is C4 Therapeutics stock price valuation
P/E
N/A
P/B
1.35
P/S
16.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.43
The EPS has increased by 2.9% since the previous quarter
The price to book (P/B) is 93% higher than the last 4 quarters average of 0.7
C4 Therapeutics's equity has decreased by 15% YoY but it has increased by 14% QoQ
CCCC's price to sales (P/S) is 102% more than its last 4 quarters average of 8.0
The company's revenue fell by 33% YoY but it rose by 2% QoQ

Efficiency

How efficient is C4 Therapeutics business performance
The return on sales has dropped by 54% year-on-year but it has increased by 3.5% since the previous quarter
C4 Therapeutics's return on invested capital has decreased by 45% YoY and by 11% QoQ
C4 Therapeutics's ROE has decreased by 42% YoY and by 2.6% from the previous quarter
The company's return on assets fell by 33% YoY

Dividends

What is CCCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CCCC.

Financial health

How did C4 Therapeutics financials performed over time
C4 Therapeutics's total assets is 189% more than its total liabilities
The quick ratio has declined by 14% since the previous quarter
The current ratio is down by 14% QoQ
The company's debt is 71% lower than its equity
The company's debt fell by 19% YoY
C4 Therapeutics's equity has decreased by 15% YoY but it has increased by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.